LTRN•benzinga•
EXCLUSIVE: Lantern Pharma Tell Benzinga 'Drug candidate LP-184 to be evaluated in combination with immune checkpoint inhibitors in biomarker-defined NSCLC patients with KEAP1 and/or STK11 mutations and low PD-L1 expression'
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 12, 2025 by benzinga